Lifitegrast
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Lifitegrast: From Dry Eye Disease to Penile Fibromatosis
One-Sentence Summary
Lifitegrast (Xiidra) is an LFA-1 antagonist originally approved for dry eye disease; it is not marketed in Taiwan. The TxGNN model’s top-ranked prediction for this drug is Penile Fibromatosis (Peyronie’s disease), but this signal is currently supported by 0 clinical trials and 0 publications — it is a pure model prediction with no mechanistic or clinical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dry Eye Disease (Xiidra) — not TFDA-approved; drug not marketed in Taiwan |
| Predicted New Indication | Penile Fibromatosis |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The formal original_moa field for lifitegrast is a data gap. However, the evidence pack’s own rationale text (attached to a different candidate indication) identifies lifitegrast as an LFA-1 (integrin αLβ2) antagonist that blocks the LFA-1/ICAM-1 interaction to suppress T-cell adhesion and activation — its only approved use being dry eye disease.
Penile fibromatosis (Peyronie’s disease) is pathologically driven by TGF-β–mediated myofibroblast proliferation and fibrosis, a mechanism distinct from T-cell adhesion inhibition. The evidence pack explicitly states there is no known mechanistic link between LFA-1 antagonism and this fibrotic pathway.
Notably, the top four TxGNN predictions for this drug (penile fibromatosis, palmar fibromatosis, Ledderhose disease, infantile digital fibromatosis) all cluster in a narrow 0.9953–0.9959 score band. This pattern suggests the model is scoring based on a shared embedding for “fibromatosis”-type diseases as a class, rather than detecting a drug-specific signal — a strong indicator that this is model-artifact clustering rather than a genuine biological hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but it is unsupported by any clinical trial, publication, or plausible mechanistic link — the drug’s known LFA-1 pathway has no established connection to the TGF-β–driven fibrosis underlying Peyronie’s disease, and the score pattern across related fibromatoses suggests a disease-class artifact rather than a drug-specific signal. This is L5/S0 evidence, the lowest tier in the framework.
To proceed, the following is needed:
- TFDA/FDA label data on warnings and contraindications (currently blocking — flagged as DG001, “Blocking” severity, preventing any S1 safety evaluation)
- Confirmed mechanism of action via DrugBank API (DG002)
- Preclinical or in-vitro evidence testing LFA-1/ICAM-1 pathway involvement in fibromatosis pathogenesis before any clinical evidence-generation is warranted
- Note: within this same evidence pack, rank 6 (diabetic retinopathy, score 99.03%) has an actual Phase 1/2 trial and 2 supporting publications, reaching L4/S1 (“Research Question”) — that candidate has a materially stronger evidence base than this top-ranked one and may merit separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.